

CONTACT:

Mary Vogel
Pittsburgh Life Sciences Greenhouse
Phone: (412) 770-1623
Email: mvogel@plsg.com



Pittsburgh Life Sciences Greenhouse takes investor lead in ARIEL Precision Medicine’s tailored therapeutic approaches for complex diseases.

PITTSBURGH, Pa. – March 30, 2017 – [Pittsburgh Life Sciences Greenhouse](#) (PLSG), Western Pennsylvania’s only investment firm dedicated to life sciences, announced today that they are the first to invest in ARIEL Precision Medicine.

Today it’s becoming easier to obtain genetic information of an individual’s personal genetic profile. However, this genetic information is imprecise and does not indicate the likelihood of a disease progression, nor timing. Precision medicine allows for individual genetic data to be matched to an individual’s personal health record to track health status. This information is fed back into a big data system to learn from like patients. Machine learning algorithms, which allow computer programs to change when exposed to new information, provide continuous improvement in prediction of disease timing and best treatment.

ARIEL Precision Medicine is an innovative biotechnology company dedicated to delivering precision medicine for patients with complex chronic diseases and disorders. ARIEL’s aim is to create a paradigm shift in healthcare delivery by integrating a patient’s symptoms and clinical history with data from a proprietary advanced genetic test.

The company’s first focus is pancreatic disease which affects 2 million new patients annually. ARIEL seeks to be able to diagnose these cases before they develop into these more aggressive later stage diseases. ARIEL’s lead products, PancreasDx®, a next generation pancreatic genetic test, and patented platform technology integrate to produce reports that empower physicians to move from a reactive treatment plan based on symptoms to a proactive treatment plan based on genetic information, clinical data, environmental factors, and ancestral information, something currently not done in this field. ARIEL’s analysis and reports provide a comprehensive picture of disease mechanism and trajectories and appropriate patient-specific therapeutic options – this is Precision Medicine.

“Precision medicine is about providing the right information to the right people at the right time” Hank Safferstein, Executive-in-Residence, Pharmaceuticals, “By utilizing advanced genetics to identify contributing and causative factors for a patient’s symptoms you can provide tailored therapeutic recommendations.”

“PLSG was the first to invest in ARIEL because they quickly understood how our integrated genomics and digital health platform facilitate precision medicine.” Jessica Gibson, CEO, ARIEL Precision Medicine. “This is really the way of the future for complex diseases. And now that PLSG has given us their ‘stamp of approval’ I’m confident others will provide follow-on dollars.”

“What makes this technology so perfect for PLSG investment, is the combination of genomics and a digital platform. “Diana Cugliari, Senior Executive Associate, Healthcare Information Technology, “We are uniquely positioned to provide guidance and support ARIEL’s growth and success’.

ARIEL’s founder, David Whitcomb MD PhD, a physician scientist who has dedicated his career to understanding and treating pancreatic diseases recognized as one of world’s experts in his field, will be hosting the world renowned Pancreasfest 2017, July 26-28, in Pittsburgh, Pennsylvania where pancreas physicians and translational researchers convene to find new ways of working together to improve patient care.

For more information about the PLSG, please visit: www.plsg.com or call 412-201-7370

About Pittsburgh Life Sciences Greenhouse (PLSG) (www.plsg.com)

The PLSG is Western Pennsylvania’s only investment firm dedicated to life sciences. By investing and supporting the growth of only bioscience companies, PLSG has developed a process to identify ‘winning ideas.’ Success is measured by the ability to attract and grow life sciences companies in the region. Since its inception in 2002, PLSG has assisted more than 450 life sciences companies and has helped create more than 2,300 jobs and has positively impacted another 14,300 jobs in Western Pennsylvania. Forty companies have been provided with office or laboratory space, and now 14 companies and 15 C-level executives have been relocated to Pittsburgh from outside of region. In addition, the PLSG has invested directly and indirectly more than \$22 million in nearly 80 companies, which has leveraged nearly \$1.8 billion in additional capital to the region.

About ARIEL Precision Medicine (www.ARIELmedicine.com)

ARIEL Precision Medicine is an integrated genomic & digital health company dedicated to delivering precision medicine solutions for Complex Chronic Diseases. Many different diseases have the same symptoms, making the right diagnosis and treatment incredibly challenging. ARIEL is revolutionizing the treatment of complex diseases by providing clinical decision support tools to physicians, allowing them to address the underlying cause of diseases prior to irreversible end-stage organ damage. ARIEL’s lead products, PancreasDx®, a next generation pancreatic genetic test and patented platform are targeted to the 2 million new patients affected by pancreatic diseases every year. ARIEL’s mission is to that empower physicians with informative reporting to move from a reactive treatment plan based on symptoms to a proactive treatment plan based on genetic information, environment triggers, and medical history. By providing a comprehensive picture of these disease mechanisms will allow for the management and therapies to be truly patient-specific. This is the future of healthcare.

###